


Delivering Our Late-Stage Programs that are Starting to Transform Lives and Generate Significant Value




1. **Zasocitinib Ph2b UC study topline result:** Clinical remission rate at week 12 showed strong separation from placebo and a nominally significant p-value at one of the two doses tested. We did not observe a dose dependent efficacy effect. Clinical remission rate in the effective dose arm was on par with other investigational oral products in Ph2 UC studies. The safety results continue to be consistent with previous trials across all dose arms. We are moving forward with planning for Phase 3 studies in UC and Crohn's disease, with final go/no-go decisions expected to be made following further data analysis of the UC-2001 and CD-2001 studies.

2. Head-to-head trial vs. deucravacitinib; 3. Latitude PsO 3003 study open label cohort [NCT06550076](#): Part A de novo patients

All timelines are approximate estimates as of October 29th, 2026, subject to change and subject to clinical and regulatory success. Table only shows selected R&D milestones and is not comprehensive.

For full glossary of abbreviations please refer to appendix. Late-stage program: Program in or expected to be in potential pivotal trial or having achieved proof-of-concept.

Delivering Our Late-Stage Programs that are Starting to Transform Lives and Generate Significant Value




1. Innovent is running early-stage trials in additional indications.

2. TAK-881 indications EU: PID, SID, CIDP; Japan: PID, SID, CIDP, MMN

All timelines are approximate estimates as of October 29th, 2026, subject to change and subject to clinical and regulatory success. Table only shows selected R&D milestones and is not comprehensive. For full glossary of abbreviations please refer to appendix. Late-stage program: Program in or expected to be in potential pivotal trial or having achieved proof-of-concept.

Maximizing Potential of Marketed Portfolio Through LCM Expansions



1. TAK-755 is the development code for recombinant ADAMTS13
2. QDENG approved in Australia (April 2026), India (July 2026)

All timelines are approximate estimates as of October 29th, 2026, subject to change and subject to clinical and regulatory success. Table only shows selected R&D milestones and is not comprehensive. For full glossary of abbreviations please refer to appendix.

Glossary of Abbreviations



Regional Abbreviations:

CN: China; EU: Europe; JP: Japan; U.S.: United States of America

1L	first line
2L	second line
3L	third line
AA	anemia-associated
AATD	α 1-antitrypsin deficiency
ADAMTS13	a disintegrin-like and metalloproteinase with a thrombospondin type 1 motifs 13
ADC	antibody–drug conjugate
AE	adverse event
AE	autoimmune encephalitis
AI	artificial intelligence
AMR	antibody-mediated rejection
AT	arcotatug tavatecan
BID	bis in die, twice a day
BDT	breakthrough therapy designation
CEO	chief executive officer
CI	confidence interval
CIDP	chronic inflammatory demyelinating polyradiculoneuropathy
CLDN18.2	claudin 18.2
CML	chronic myeloid leukemia
cORR	confirmed objective response rate
CP-CML	chronic-phase chronic myeloid leukemia
CRC	colorectal cancer
cTTP	congenital thrombotic thrombocytopenic purpura
CY	calendar year
DOAC	direct oral anti-coagulation
EADV	European Academy of Dermatology and Venereology
EMA	European Medicines Agency
EQ-5D-5L	EuroQoL-5 Dimensions 5-levels
ESMO	European Society for Medical Oncology
Fc	fragment crystallizable
FDA	U.S. Food & Drug Administration
FINI	Functional Impacts of Narcolepsy Instrument
FSI	first subject in

FY	fiscal year
GC	gastric cancer
GI	gastrointestinal
hfPGA	hands and/or feet-specific Physician's Global Assessment
HR	hazard ratio
HS	hidradenitis suppurativa
H2H	head-to-head
IBD	inflammatory bowel disease
IgA	immunoglobulin A
IgAN	immunoglobulin A nephropathy
IgG	immunoglobulin G
IH	idiopathic hypersomnia
IL-2/12/17/23	interleukin 2/12/17/23
IND	investigational new drug
ITP	immune thrombocytopenia
IV	intravenous
JPY	Japanese Yen
LCM	lifecycle management
MDS	myelodysplastic syndrome
MF	myelofibrosis
MMN	multifocal motor neuropathy
MSS CRC	microsatellite-stable colorectal cancer
NDA	new drug application
NME	new molecular entity
NMPA	(China's) National Medical Products Administration
NSCLC	non-small cell lung cancer
nsqNSCLC	non-squamous non-small cell lung cancer
NSS-CT	Narcolepsy Severity Scale for Clinical Trials
NT1 or 2	narcolepsy type 1 or 2
ORR	objective response rate
OS	overall survival
OX2R	orexin receptor 2
PASI	Psoriasis Area and Severity Index
PD-1	programmed cell death protein 1

PDAC	pancreatic ductal adenocarcinoma
PDT	plasma derived therapies
PDUFA	Prescription Drug User Fee Act
PFS	progression-free survival
PGA	Physician's Global Assessment
Ph1, Ph2, Ph3	phase 1, 2, 3
PID	primary immunodeficiency
PMDA	Japan's Pharmaceuticals and Medical Devices Agency
POC	proof of concept
PRIME	Priority medicines scheme by EMA
PROC	platinum-resistant ovarian cancer
PsA	psoriatic arthritis
PsO	psoriasis
PSOC	platinum-sensitive ovarian cancer
PV	polycythemia vera
QOL	quality of life
R&D	Research and Development
REM	rapid eye movement
SC	subcutaneous formulation
SF-36	Short Form-36 Survey
SID	secondary immunodeficiency
SOC	standard of care
sqNSCLC	squamous non-small cell lung cancer
ssPGA	scalp-specific Physician's Global Assessment
TNFα	tumor necrosis factor alpha
TPC	treatment of physician's choice
TRAE	treatment-related adverse event
TYK2	tyrosine kinase 2
UC	ulcerative colitis
UEG(W)	United European Gastroenterology (Week)
USD	US dollar
wk(s)	week(s)
WW	worldwide